Abbott Laboratories (Pakistan) Limited reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was PKR 12,271.01 million compared to PKR 10,649.31 million a year ago. Revenue was PKR 12,271.01 million compared to PKR 10,649.31 million a year ago. Net income was PKR 784.97 million compared to PKR 1,209.91 million a year ago. Basic earnings per share from continuing operations was PKR 8.02 compared to PKR 12.36 a year ago.
For the nine months, sales was PKR 36,951.44 million compared to PKR 31,447.29 million a year ago. Revenue was PKR 36,951.44 million compared to PKR 31,447.29 million a year ago. Net income was PKR 2,564.98 million compared to PKR 4,491.9 million a year ago. Basic earnings per share from continuing operations was PKR 26.2 compared to PKR 45.88 a year ago.